Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

3D Systems ($DDD) Forms Systemic Bio to Accelerate Drug Discovery and Development

Green Stock News LLC
 

 

September 9, 2022 – TheNewswire - 3D Systems (DDD) has announced the formation of a new wholly owned company named Systemic Bio. The new biotech company will focus on the application of advanced bio-printing technologies for pharmaceutical drug discovery and development. 

 

The company says that Systemic Bio will leverage its breakthrough production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities and then perfused with desired drug compounds to study drug metabolism and the effects on healthy or diseased tissue at early stages of new pharmaceutical drug development. 

 

The ability to accurately simulate human response to an experimental drug in the laboratory, early in the development process, will offer the potential to significantly reduce both high costs and extended timelines required for pharmaceutical companies to bring new drugs to market. Additionally, the company says that this approach could eventually reduce or even eliminate the need for animal testing as a precursor to full-scale human trials for new drug development.

 

Dr. Jeffrey Graves, President and CEO of 3D Systems stated: “I am pleased and inspired by the progress we continue to make in the emerging field of regenerative medicine. The complexity and precision that we have now demonstrated using biocompatible materials and our most advanced production bioprinting platform technology is truly groundbreaking, opening a host of new applications ranging from the laboratory to replacement organs within the human body.”

 

3D Systems says that it will provide $15 million in seed funding to demonstrate efficacy of the technology and associated business model. The company is targeting revenues for Systemic Bio to approach $100 million annually within five years.


Shares of 3D Systems trade on the NYSE under the ticker symbol DDD. For more information visit www.greenstocknews.com

 

Disclaimer

 

This content is not financial advice and is for information, education and entertainment purposes only. Green Stock News is not responsible for any losses related to the financial decisions made by you. Video content and other materials including web content are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Green Stock News is not responsible for any gains or losses that result from the opinions expressed in this video or materials that it publishes electronically.

 

View original video news clips here: https://greenstocknews.com/green-stock-newswire 

  

Copyright (c) 2022 TheNewswire - All rights reserved.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.